Fulcrum Therapeutics, Inc. (FULC)
FULC Stock Price Chart
Explore Fulcrum Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze FULC price movements and trends.
FULC Company Profile
Discover essential business fundamentals and corporate details for Fulcrum Therapeutics, Inc. (FULC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jul 2019
Employees
55.00
Website
https://www.fulcrumtx.comCEO
Alexander C. Sapir
Description
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
FULC Financial Timeline
Browse a chronological timeline of Fulcrum Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.21.
Earnings released on 27 Apr 2026
EPS came in at -$0.25 surpassing the estimated -$0.31 by +19.35%.
Earnings released on 24 Feb 2026
EPS came in at -$0.31 matching the estimated -$0.31.
Earnings released on 29 Oct 2025
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%.
Earnings released on 29 Jul 2025
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%.
Earnings released on 1 May 2025
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%.
Earnings released on 25 Feb 2025
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%.
Earnings released on 13 Nov 2024
EPS came in at -$0.35 surpassing the estimated -$0.40 by +12.50%.
Earnings released on 31 Jul 2024
EPS came in at $0.87 surpassing the estimated -$0.06 by +1.55k%, while revenue for the quarter reached $80.00m , beating expectations by +439.93%.
Earnings released on 13 May 2024
EPS came in at -$0.43 surpassing the estimated -$0.44 by +2.27%.
Earnings released on 27 Feb 2024
EPS came in at -$0.40 surpassing the estimated -$0.44 by +9.09%, while revenue for the quarter reached $871.00k , beating expectations by +57.58%.
Earnings released on 7 Nov 2023
EPS came in at -$0.39 surpassing the estimated -$0.44 by +11.36%, while revenue for the quarter reached $759.00k , missing expectations by -27.86%.
Earnings released on 3 Aug 2023
EPS came in at -$0.38 surpassing the estimated -$0.44 by +13.64%, while revenue for the quarter reached $880.00k , missing expectations by -21.12%.
Earnings released on 15 May 2023
EPS came in at -$0.41 surpassing the estimated -$0.47 by +12.77%, while revenue for the quarter reached $295.00k , missing expectations by -72.35%.
Earnings released on 9 Mar 2023
EPS came in at -$0.50 falling short of the estimated -$0.49 by -2.04%, while revenue for the quarter reached $685.00k , missing expectations by -63.76%.
Earnings released on 8 Nov 2022
EPS came in at -$0.50 surpassing the estimated -$0.62 by +19.35%, while revenue for the quarter reached $1.18m , missing expectations by -53.48%.
Earnings released on 11 Aug 2022
EPS came in at -$0.83 falling short of the estimated -$0.66 by -25.76%, while revenue for the quarter reached $1.88m , missing expectations by -36.51%.
Earnings released on 9 May 2022
EPS came in at -$0.64 falling short of the estimated -$0.63 by -1.59%, while revenue for the quarter reached $2.59m , missing expectations by -34.28%.
Earnings released on 3 Mar 2022
EPS came in at -$0.58 surpassing the estimated -$0.73 by +20.28%, while revenue for the quarter reached $5.06m , beating expectations by +88.74%.
Earnings released on 4 Nov 2021
EPS came in at -$0.57 surpassing the estimated -$0.64 by +10.94%, while revenue for the quarter reached $4.94m , beating expectations by +119.33%.
Earnings released on 10 Aug 2021
EPS came in at -$0.60 surpassing the estimated -$0.65 by +7.69%, while revenue for the quarter reached $4.38m , beating expectations by +173.81%.
FULC Stock Performance
Access detailed FULC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
